Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2023

05-11-2022 | Pancreatic Cancer | Original Article

Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]Ga-FAPI-04

Authors: Ruohua Chen, Xinlan Yang, Xiaofeng Yu, Xiang Zhou, Yee Ling Ng, Haitao Zhao, Lianghua Li, Gang Huang, Yun Zhou, Jianjun Liu

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2023

Login to get access

Abstract

Purpose

[68Ga]Ga-FAPI PET/CT has been widely used in clinical diagnosis and radiopharmaceutical therapy. In this study, tumor-to-blood ratio (TBR) was evaluated as a powerful tool for semiquantitative assessment of [68Ga]Ga-FAPI-04 tumor uptake and as an effective index for tumors with high FAP expression in theranostics.

Methods

Nine patients with pancreatic cancer underwent a 60-min dynamic PET/CT scan by total-body PET/CT (with a long AFOV of 194 cm) after injection of [68Ga]Ga-FAPI-04. After dynamic PET/CT scan, three patients received chemotherapy and underwent the second dynamic scan to evaluate treatment response. Time-activity curves (TACs) were obtained by drawing regions of interest for primary pancreatic lesions and metastatic lesions. The lesion TACs were fitted using four compartment models by the software PMOD PKIN kinetic modeling. The preferred pharmacokinetic model for [68Ga]Ga-FAPI-04 was evaluated based on the Akaike information criterion. The correlations between simplified methods for quantification of [68Ga]Ga-FAPI-04 (SUVs; tumor-to-blood ratios [TBRs]) and the total distribution volume (Vt) estimates obtained from pharmacokinetic analysis were calculated.

Results

In total, 9 primary lesions and 25 metastatic lesions were evaluated. The reversible two-tissue compartment model (2TCM) was the most appropriate model among the four compartment models. The total distribution volume Vt values derived from 2TCM varied significantly in pathological lesions and background regions. A strong positive correlation was observed between TBRmean and Vt from the 2TCM model in pathological lesions (R2=0.92, P<0.001). The relative difference range for TBRmean was 2.1% compared to the reduction rate of Vt in the patients who were treated with chemotherapy.

Conclusions

A strong positive correlation was observed between TBRmean and Vt for [68Ga]Ga-FAPI-04. TBRmean reflects FAP receptor density better than SUVmean and SUVmax, and would be the preferred measurement tool for semiquantitative assessment of [68Ga]Ga-FAPI-04 tumor uptake and as a means for evaluating treatment response.
Appendix
Available only for authorised users
Literature
1.
go back to reference Xia N, Yang N, Shan Q, et al. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022;26:2322–36.CrossRef Xia N, Yang N, Shan Q, et al. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022;26:2322–36.CrossRef
2.
go back to reference Ogawa Y, Masugi Y, Abe T, et al. Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen. Clin Cancer Res. 2021;27:107–19.CrossRef Ogawa Y, Masugi Y, Abe T, et al. Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen. Clin Cancer Res. 2021;27:107–19.CrossRef
3.
go back to reference Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18:840–6.CrossRef Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012;18:840–6.CrossRef
4.
go back to reference Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRef Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415–22.CrossRef
5.
go back to reference Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.CrossRef Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423–9.CrossRef
6.
go back to reference Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT Imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.CrossRef Rohrich M, Naumann P, Giesel FL, et al. Impact of (68)Ga-FAPI PET/CT Imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62:779–86.CrossRef
7.
go back to reference Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022; 49:2877–88. Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET/MR and (18)F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022; 49:2877–88.
8.
go back to reference Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415–23.CrossRef Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415–23.CrossRef
9.
go back to reference Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using (68)Ga-DOTATOC and (68)Ga-DOTATATE. J Nucl Med. 2020;61:217–21.CrossRef Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using (68)Ga-DOTATOC and (68)Ga-DOTATATE. J Nucl Med. 2020;61:217–21.CrossRef
10.
go back to reference Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.CrossRef Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.CrossRef
11.
go back to reference Haug AR, Auernhammer CJ, Wangler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.CrossRef Haug AR, Auernhammer CJ, Wangler B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51:1349–56.CrossRef
12.
go back to reference Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.CrossRef Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635–52.CrossRef
13.
go back to reference Ding W, Yu J, Zheng C, et al. Machine Learning-based noninvasive quantification of single-imaging session dual-tracer (18)F-FDG and (68)Ga-DOTATATE dynamic PET-CT in oncology. IEEE Trans Med Imaging. 2022;41:347–59.CrossRef Ding W, Yu J, Zheng C, et al. Machine Learning-based noninvasive quantification of single-imaging session dual-tracer (18)F-FDG and (68)Ga-DOTATATE dynamic PET-CT in oncology. IEEE Trans Med Imaging. 2022;41:347–59.CrossRef
14.
go back to reference Liu M, Paranjpe MD, Zhou X, et al. Sex modulates the ApoE epsilon4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959–70.CrossRef Liu M, Paranjpe MD, Zhou X, et al. Sex modulates the ApoE epsilon4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959–70.CrossRef
15.
go back to reference Zhao Q, Chen X, Zhou Y. Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform. 2016;3:29–37.CrossRef Zhao Q, Chen X, Zhou Y. Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform. 2016;3:29–37.CrossRef
16.
go back to reference Zhou Y, Ye W, Brasic JR, Wong DF. Multi-graphical analysis of dynamic PET. Neuroimage. 2010;49:2947–57.CrossRef Zhou Y, Ye W, Brasic JR, Wong DF. Multi-graphical analysis of dynamic PET. Neuroimage. 2010;49:2947–57.CrossRef
17.
go back to reference Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975–89.CrossRef Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975–89.CrossRef
19.
go back to reference Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.CrossRef Zhang X, Xie Z, Berg E, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2020;61:285–91.CrossRef
20.
go back to reference Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.CrossRef Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.CrossRef
21.
go back to reference Koopman T, Verburg N, Schuit RC, et al. Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Res. 2018;8:72.CrossRef Koopman T, Verburg N, Schuit RC, et al. Quantification of O-(2-[(18)F]fluoroethyl)-L-tyrosine kinetics in glioma. EJNMMI Res. 2018;8:72.CrossRef
22.
go back to reference Ringheim A, Campos Neto GC, Anazodo U, et al. Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10:12.CrossRef Ringheim A, Campos Neto GC, Anazodo U, et al. Kinetic modeling of (68)Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10:12.CrossRef
23.
go back to reference Slaets D, De Vos F. Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice. EJNMMI Res. 2013;3:66.CrossRef Slaets D, De Vos F. Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice. EJNMMI Res. 2013;3:66.CrossRef
24.
go back to reference Dendl K, Schlittenhardt J, Staudinger F, et al. The role of fibroblast activation protein ligands in oncologic PET imaging. PET Clin. 2021;16:341–51.CrossRef Dendl K, Schlittenhardt J, Staudinger F, et al. The role of fibroblast activation protein ligands in oncologic PET imaging. PET Clin. 2021;16:341–51.CrossRef
25.
go back to reference Coughlin JM, Slania S, Du Y, et al. (18)F-XTRA PET for enhanced imaging of the extrathalamic alpha4beta2 nicotinic acetylcholine receptor. J Nucl Med. 2018;59:1603-1608. Coughlin JM, Slania S, Du Y, et al. (18)F-XTRA PET for enhanced imaging of the extrathalamic alpha4beta2 nicotinic acetylcholine receptor. J Nucl Med. 2018;59:1603-1608.
26.
go back to reference Iqbal R, Kramer GM, Frings V, et al. Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018;8:22.CrossRef Iqbal R, Kramer GM, Frings V, et al. Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. EJNMMI Res. 2018;8:22.CrossRef
27.
go back to reference Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57.CrossRef Pure E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57.CrossRef
28.
go back to reference Kilvaer TK, Khanehkenari MR, Hellevik T, et al. Cancer associated fibroblasts in Stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers. PLoS ONE. 2015;10:e0134965.CrossRef Kilvaer TK, Khanehkenari MR, Hellevik T, et al. Cancer associated fibroblasts in Stage I-IIIA NSCLC: prognostic impact and their correlations with tumor molecular markers. PLoS ONE. 2015;10:e0134965.CrossRef
Metadata
Title
Tumor-to-blood ratio for assessment of fibroblast activation protein receptor density in pancreatic cancer using [68Ga]Ga-FAPI-04
Authors
Ruohua Chen
Xinlan Yang
Xiaofeng Yu
Xiang Zhou
Yee Ling Ng
Haitao Zhao
Lianghua Li
Gang Huang
Yun Zhou
Jianjun Liu
Publication date
05-11-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-06010-5

Other articles of this Issue 3/2023

European Journal of Nuclear Medicine and Molecular Imaging 3/2023 Go to the issue